GILEAD SCIENCES, INC. STOCK OPTION AGREEMENTStock Option Agreement • May 9th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
GILEAD SCIENCES, INC. RESTRICTED STOCK UNIT ISSUANCE AGREEMENTRestricted Stock Unit Issuance Agreement • May 9th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
GILEAD SCIENCES, INC. PERFORMANCE SHARE AWARD AGREEMENTPerformance Share Award Agreement • May 9th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
AGREEMENT AND PLAN OF MERGER BY AND AMONG GILEAD SCIENCES, INC., GILEAD BIOPHARMACEUTICS IRELAND CORPORATION, GILEAD SCIENCES LIMITED, CALISTOGA PHARMACEUTICALS, INC. and SHAREHOLDER REPRESENTATIVE SERVICES LLC, AS STOCKHOLDERS’ AGENT Dated as of...Agreement and Plan of Merger • May 9th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of February 21, 2011 by and among Gilead Sciences, Inc., a Delaware corporation (“Guarantor”), Gilead Biopharmaceutics Ireland Corporation, a company formed under the laws of Ireland (“Parent”), Gilead Sciences Limited, a company formed under the laws of Ireland and a wholly owned subsidiary of Parent (“Merger Sub”), Calistoga Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as a Stockholders’ Agent hereunder (the “Stockholders’ Agent”).
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • May 9th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
This AMENDMENT NO. 1 (this “Amendment”) to the Agreement and Plan of Merger, dated as of February 21, 2011 (the “Agreement”), by and among Gilead Sciences, Inc., a Delaware corporation (“Guarantor”), Gilead Biopharmaceutics Ireland Corporation, a company formed under the laws of Ireland (“Parent”), Hot Springs Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (as successor in interest to Gilead Sciences Limited) (“Merger Sub”), Calistoga Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as a Stockholders’ Agent hereunder (the “Stockholders’ Agent”) is entered into as of March 24, 2011 in accordance with Section 10.11 of the Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.
GILEAD SCIENCES LIMITED – PHARMACHEM TECHNOLOGIES (GRAND BAHAMA), LTD. ADDENDUM TO TENOFOVIR DISOPROXIL FUMARATE MANUFACTURING SUPPLY AGREEMENTSupply Agreement • May 9th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
This Addendum agreement (the “Addendum”) is entered into as of February 3, 2011 by and between PharmaChem Technologies (Grand Bahama) Ltd., a Commonwealth of the Bahamas company (“PharmaChem”) having its principal place of business at West Sunrise Highway, Freeport, Grand Bahama, Commonwealth of the Bahamas, and Gilead Sciences Limited, an Irish limited company (“GSL”) whose registered address is Unit 12, Stillorgan Industrial Park, Blackrock, Co. Dublin, Ireland. PharmaChem and GSL may be referred to individually as a “Party” and collectively as the “Parties” in this Addendum.
